Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Free Cash Flow: 2019-2024

Historic Free Cash Flow for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$138.4 million.

  • 4D Molecular Therapeutics' Free Cash Flow fell 48.89% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$185.1 million, marking a year-over-year decrease of 58.49%. This contributed to the annual value of -$138.4 million for FY2024, which is 76.13% down from last year.
  • 4D Molecular Therapeutics' Free Cash Flow amounted to -$138.4 million in FY2024, which was down 76.13% from -$78.6 million recorded in FY2023.
  • 4D Molecular Therapeutics' 5-year Free Cash Flow high stood at -$51.9 million for FY2020, and its period low was -$138.4 million during FY2024.
  • In the last 3 years, 4D Molecular Therapeutics' Free Cash Flow had a median value of -$98.2 million in 2022 and averaged -$105.1 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Free Cash Flow rose by 20.01% in 2023, and later slumped by 76.13% in 2024.
  • 4D Molecular Therapeutics' Free Cash Flow (Yearly) stood at -$51.9 million in 2020, then tumbled by 50.73% to -$78.2 million in 2021, then decreased by 25.53% to -$98.2 million in 2022, then climbed by 20.01% to -$78.6 million in 2023, then crashed by 76.13% to -$138.4 million in 2024.